SEC Form 4 · accession 0001209191-16-149948
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Wiezorek
Officer — SVP Clinical Development
Period of report
Nov 10, 2016
Accepted (ET)
Nov 14, 2016 · 6:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 10, 2016 | M | 1,500 | $6.89 | A | 17,311 | D | |
| Common Stock | Nov 10, 2016 | S | 1,500 | $50.18 | D | 15,811 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $6.89 | Nov 10, 2016 | M | 1,500 | D | — | Jun 5, 2024 | Common Stock | 1,500 | 76,208 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2016.
- F225% of the 175,000 shares subject to the stock option vested and became exercisable on May 5, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.